Three previous clinical trials in China [33, 34, 43] have shown that QSHY significantly reduces ALT and AST in patients with NAFLD and can reduce serum TG and TC, which indicates that QSHY has a therapeutic effect on patients with NAFLD and hyperlipidemia. Here, GPT is linked to hyperlipidemia.